1
|
Diagnostic markers for early detection of ovarian cancer.
|
Clin Cancer Res
|
2008
|
6.47
|
2
|
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
|
Cell Cycle
|
2009
|
3.60
|
3
|
Serum protein markers for early detection of ovarian cancer.
|
Proc Natl Acad Sci U S A
|
2005
|
3.22
|
4
|
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
|
Cancer Res
|
2006
|
3.21
|
5
|
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
|
Cancer Res
|
2010
|
2.15
|
6
|
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells.
|
Oncogene
|
2003
|
1.65
|
7
|
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
|
Cancer
|
2006
|
1.27
|
8
|
Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes.
|
J Immunol
|
2003
|
1.22
|
9
|
Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.
|
Oncol Res
|
2004
|
1.20
|
10
|
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.
|
J Oncol
|
2011
|
1.15
|
11
|
Macrophage migration inhibitory factor expression in ovarian cancer.
|
Am J Obstet Gynecol
|
2007
|
1.09
|
12
|
Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
|
J Soc Gynecol Investig
|
2004
|
1.08
|
13
|
Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer.
|
Int J Cancer
|
2011
|
1.03
|
14
|
Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma.
|
Cancer Lett
|
2002
|
1.03
|
15
|
Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
|
Int J Surg Pathol
|
2004
|
1.02
|
16
|
Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells.
|
Am J Reprod Immunol
|
2010
|
0.99
|
17
|
Cesarean scar ectopic pregnancy: case series and review of the literature.
|
Am J Perinatol
|
2009
|
0.99
|
18
|
Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells.
|
Biol Reprod
|
2002
|
0.98
|
19
|
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
|
Cancer Med
|
2013
|
0.95
|
20
|
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.
|
Yale J Biol Med
|
2006
|
0.93
|
21
|
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells.
|
J Soc Gynecol Investig
|
2006
|
0.91
|
22
|
MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
|
Gynecol Oncol
|
2011
|
0.90
|
23
|
Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience.
|
Int J Gynecol Cancer
|
2014
|
0.88
|
24
|
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
|
Am J Obstet Gynecol
|
2013
|
0.88
|
25
|
Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
|
Gynecol Oncol
|
2005
|
0.87
|
26
|
High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
|
Reprod Sci
|
2012
|
0.86
|
27
|
Regulation of Fas ligand expression by estrogen in normal ovary.
|
J Soc Gynecol Investig
|
2002
|
0.84
|
28
|
Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray.
|
Int J Mol Med
|
2004
|
0.83
|
29
|
Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells.
|
Mol Hum Reprod
|
2002
|
0.82
|
30
|
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
|
Gynecol Oncol
|
2013
|
0.81
|
31
|
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
|
Int J Gynecol Cancer
|
2014
|
0.77
|
32
|
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
|
Int J Gynecol Cancer
|
2015
|
0.76
|
33
|
HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
|
Histopathology
|
2010
|
0.76
|
34
|
Phase I study of perillyl alcohol in patients with refractory malignancies.
|
Cancer Biol Ther
|
2002
|
0.76
|
35
|
Benign multicystic mesothelioma: a case report of three sisters.
|
Rare Tumors
|
2009
|
0.75
|
36
|
Anti-tumor activity of phenoxodiol: from bench to clinic.
|
Future Oncol
|
2008
|
0.75
|
37
|
Genotyping diagnosis of nongestational choriocarcinoma involving fallopian tube and broad ligament: a case study.
|
Int J Gynecol Pathol
|
2014
|
0.75
|